What's fueling the biotech engine—2011 to 2012

Bevacizumab in the Treatment of Ovarian Cancer

(2012) Florian Heitz et al.   ADVANCES IN THERAPY

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

(2012) R. A. de Claro et al.   CLINICAL CANCER RESEARCH

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Past 200 Years in Diabetes

(2012) Kenneth S. Polonsky   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

(2011) Bernard Zinman et al.   LANCET

What's fueling the biotech engine—2010 to 2011

(2011) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis

(2011) Ken Garber   NATURE BIOTECHNOLOGY

What's fueling the biotech engine—2009–2010

(2010) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Targeted cancer therapies

(2010) Saurabh Aggarwal   NATURE REVIEWS DRUG DISCOVERY

Is Maintenance Rituximab Now Ready for PRIMA-Time?

(2010) Paul A. Hamlin   Current Oncology Reports

What's fueling the biotech engine—2008

(2009) Saurabh Aggarwal   NATURE BIOTECHNOLOGY